Aus­tralia, home to a world-class ear­ly phase clin­i­cal tri­al ecosys­tem

5 years ago

Trans­port Sim­u­la­tion Test­ing for Your Ther­a­py is the Best Way to As­sure FDA Ex­pe­dit­ed Pro­gram Ap­proval

5 years ago

$48 Bil­lion Is Lost to Avoid­able Ex­per­i­ment Ex­pen­di­ture Every Year

6 years ago

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

6 years ago

How Aus­tralia De­liv­ers Rapid Start-up and 43.5% Re­bate for Ear­ly Phase On­col­o­gy Tri­als

6 years ago

De­cen­tral­ized Clin­i­cal Tri­als: The fu­ture of clin­i­cal tri­als is now

6 years ago

A Fast Way to Curb Drug De­vel­op­ment Costs? Make Fail­ure a Strat­e­gy.

6 years ago

Tak­ing Ac­tion to En­sure Clin­i­cal Tri­al Progress Dur­ing COVID-19

6 years ago

Five strate­gies for mit­i­gat­ing the im­pact of COVID-19 on clin­i­cal tri­als

6 years ago

Ven­ture Cap­i­tal as a Strate­gic Part­ner: Fu­el­ing In­no­va­tion be­yond Fi­nance

6 years ago

Ad­dress­ing Key Chal­lenges of Lipid-Me­di­at­ed De­liv­ery Sys­tems for mR­NA through In­no­va­tion

6 years ago

Zhi­meng Bio­phar­ma An­nounces the First-in-Hu­man Dos­ing in Phase I Clin­i­cal Tri­al of ZM-H1505R De­signed for the Treat­ment of Chron­ic He­pati­tis B Virus In­fec­tion

6 years ago

Lessons for biotech and phar­ma from a doc­tor who chased his own cure

6 years ago

A New Fron­tier: The In­ner Ear

6 years ago

2019 Trin­i­ty Drug In­dex Eval­u­ates Ac­tu­al Com­mer­cial Per­for­mance of Nov­el Drugs Ap­proved in 2016

6 years ago

How to cap­i­talise on a lean launch

6 years ago

Turn­ing the cor­ner on treat­ing the root cause of sick­le cell dis­ease

6 years ago

Es­sen­tial cri­te­ria bio­phar­ma­ceu­ti­cal in­vestors seek when eval­u­at­ing com­pounds and com­pa­nies

6 years ago

In­vent­ing Med­i­cine by Ac­cess­ing the Hid­den Trea­sure in the Hu­man Mi­cro­bio­me’s Dark Mat­ter

6 years ago

De­vel­op­ment of the Next Gen­er­a­tion NKG2D CAR T-cell Man­u­fac­tur­ing Process

6 years ago

Part­ner with the right bio­an­a­lyt­ics firm at start-up to de-risk drug de­vel­op­ment

6 years ago

Con­quer­ing a silent killer: HDV and Eiger Bio­Phar­ma­ceu­ti­cals

6 years ago

Com­mu­ni­cat­ing the val­ue of pre­ci­sion med­i­cine

6 years ago

Prac­ti­cal im­pli­ca­tions of re­cent FDA guid­ance on im­muno­genic­i­ty risk as­sess­ments on your IND sub­mis­sions

6 years ago
First page Previous page 67891011 Next page Last page
A service from the Financial Times